On September 23, 2025, Manas AI, a full-stack, AI native drug discovery and development company, announced the closing of a $26 million Seed Extension and the addition of its new Co-Founder and Chief Technology Officer, Ujjwal Singh. Wilson Sonsini advised Manas AI on the transaction.

Founded to address inefficiencies in traditional drug development, Manas AI aims to create faster, cheaper, and more precise medicines by integrating biomedical expertise with advanced AI technologies. The new funding will be used to accelerate the development of its drug discovery foundational models, advance its current therapeutic campaigns, and expand the team.

The Wilson Sonsini team that advised Manas AI on the transaction includes Yokum Taku, Avi Emanuel, Oliver Zhou, Jacob Morales, and Pavit Dhaliwal.

For more information, please see Manas AI's news release.